Advertisement
UK markets open in 32 minutes
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • HANG SENG

    17,709.30
    +424.76 (+2.46%)
     
  • CRUDE OIL

    84.00
    +0.43 (+0.51%)
     
  • GOLD FUTURES

    2,352.00
    +9.50 (+0.41%)
     
  • DOW

    38,085.80
    -375.12 (-0.98%)
     
  • Bitcoin GBP

    51,528.73
    +129.29 (+0.25%)
     
  • CMC Crypto 200

    1,391.92
    -4.62 (-0.33%)
     
  • NASDAQ Composite

    15,611.76
    -100.99 (-0.64%)
     
  • UK FTSE All Share

    4,387.94
    +13.88 (+0.32%)
     

Can CureVac Win Market Share With Only 48% Vaccine Efficacy?

Can CureVac Win Market Share With Only 48% Vaccine Efficacy?

CureVac (NASDAQ: CVAC) surprised investors a few weeks ago when it announced disappointing data from a trial of its mRNA vaccine candidate. Many expected the German biotech would follow in the footsteps of fellow mRNA vaccine makers Pfizer and Moderna. After the CureVac report, it looked like company's dreams of a spot in the vaccine market were over -- at least in the near term.